Want to see TCRX full AI Analyst Report?
TScan Therapeutics (TCRX) Income Statement
TScan Therapeutics Income Statement
Last quarter (Q2 2026), TScan Therapeutics's total revenue was $1.05M, a decrease of 65.83% from the same quarter last year. In Q2, TScan Therapeutics's net income was $-30.36M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 10.32M | $ 2.82M | $ 21.05M | $ 13.54M | $ 10.14M | |
| $ 7.46M | $ 2.82M | $ 21.05M | $ 13.54M | $ 10.14M | |
| $ 143.27M | $ 137.64M | $ 114.51M | $ 80.17M | $ 58.78M | |
| Depreciation and Amortization | $ 2.87M | $ 4.11M | $ 5.36M | $ 5.14M | $ 3.33M |
| $ -124.13M | $ -119.74M | $ -80.10M | $ -59.91M | $ -45.30M | |
| $ -135.81M | $ -134.82M | $ -93.46M | $ -66.64M | $ -48.64M | |
| $ 6.05M | $ 7.32M | $ 4.24M | $ 415.00K | $ 16.00K | |
| $ -129.77M | $ -127.50M | $ -89.22M | $ -66.22M | $ -48.63M | |
| $ -129.77M | $ -127.50M | $ -89.22M | $ -66.22M | $ -48.63M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.00 | $ -1.14 | $ -1.36 | $ -2.74 | $ -2.03 |
| Diluted EPS | $ -1.00 | $ -1.14 | $ -1.36 | $ -2.74 | $ -2.03 |
| Weighted Average Shares Outstanding | 129.86M | 111.99M | 65.60M | 24.05M | 23.91M |
| Weighted Average Shares Outstanding (Diluted) | 129.86M | 111.99M | 65.60M | 24.05M | 23.91M |
Currency in USD